{"prompt": "['Novartis', 'Confidential', 'Page 87', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', '100 X', 'FEV1 (post-bronchodilator) - FEV1 (pre-bronchodilator)*', 'FEV1 (pre-bronchodilator)*', 'Patients will be considered reversible if an increase of at least 12% (and 200 mL) is', 'demonstrated after administration of the salbutamol/albuterol', '*NOTE: At visits with two pre-dose spirometry assessments (please see Table 6-1 for', 'schedule of assessments) the FEV1 from the 2nd pre-dose spirometry assessment (performed', 'approximately 15 min prior to in-clinic witnessed study drug administration) should be used', 'for FEV1 (pre-bronchodilator).', '17.1', 'References for appendix', '1Miller MR et al (2005) Standardization of Lung Function Testing. Eur Resp J; 26:153-161.', '2Quanjer PH, Stanojevic S, Cole TJ, Baur X, L Hall GL, Culver B, Enright PL, Hankinson JL,', 'Zheng J, Stocks J and the ERS Global Lung Function Initiative (2012) Multi ethnic reference', 'values for spirometry for the 3-95 year age range: the global lung function 2012 equations.', 'Report of the Global Lung Function Initiative (GLI), ERS Task Force to establish improved', 'Lung Function Reference Values. Eur Resp J; 40:1324-1343.', '3Kubota, Kobayashi, Quanjer PH, et al. Reference values for spirometry, including vital', 'capacity, in Japanese adults calculated with the LMS method and compared with previous', 'values. Clinical Pulmonary Functions Committee of the Japanese Respiratory', 'Society. Respiratory Investigations 2014, 242-250.']['Novartis', 'Confidential', 'Page 88', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', '18', 'Appendix 6: Estimated equivalence of inhaled', 'corticosteroids', 'Box 8. Low, medium and high daily doses of inhaled corticosteroids (mcg)', 'Inhaled corticosteroid', 'Adults and adolescents', 'Children 6-11 years', 'Low', 'Medium', 'High', 'Low', 'Medium', 'High', 'Beclometasone dipropionate (CFC)*', '200-500', '>500-1000', '>1000', '100-200', '>200-400', '>400', 'Beclometasone dipropionate (HFA)', '100-200', '>200-400', '>400', '50-100', '>100-200', '>200', 'Budesonide (DPI)', '200-400', '>400-800', '>800', '100-200', '>200-400', '>400', 'Budesonide (nebules)', '250-500', '>500-1000', '>1000', 'Ciclesonide (HFA)', '80-160', '>160-320', '>320', '80', '>80-160', '>160', 'Fluticasone furoate (DPI)', '100', 'n.a.', '200', 'n.a.', 'n.a.', 'n.a.', 'Fluticasone propionate( DPI)', '100-250', '>250-500', '>500', '100-200', '>200-400', '>400', 'Fluticasone propionate (HFA)', '100-250', '>250-500', '>500', '100-200', '>200-500', '>500', 'Mometasone furoate', '110-220', '>220-440', '>440', '110', '>220-<440', '>440', 'Triamcinolone acetonide', '400-1000', '>1000-2000', '>2000', '400-800', '>800-1200', '>1200', '; CFC: chlorofluorocarbon propellant; DPI: dry powder inhaler; HFA: hydrofluoroalkane propellant. \"Included for comparison with older literature.', 'From the Global Strategy for Asthma Management and Prevention 2016, Global Initiative', 'for Asthma (GINA) all rights reserved. Available from http://www.ginasthma.org.', 'For the purposes of calculating total daily dose for the study, if the table has the medication', 'dose listed by dry powder inhaler (DPI), but not metered dose inhaler (MDI), then use the DPI', 'classification as a reference and vice versa (i.e., if the table has the medication dose listed by', 'MDI, but not DPI, then use the MDI classification).']\n\n###\n\n", "completion": "END"}